Browsing by Author "Kaya, AH"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
    Gemici, A; Aydogdu, I; Terzi, H; Sencan, M; Aslan, A; Kaya, AH; Dal, MS; Akay, MO; Dogu, MH; Ayyildiz, O; Sahin, F; Cagliyan, GA; Yilmaz, M; Gokgoz, Z; Bilen, Y; Demir, C; Sevindik, OG; Korkmaz, S; Eser, B; Altuntas, F
    Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.
  • No Thumbnail Available
    Item
    The outcome of eltrombopag therapy in immune thrombocytopenia: a multicenter study from Turkey
    Pamuk, GE; Maden, M; Sari, HI; Erkurt, MA; Keskinkilic, M; Cagliyan, GA; Kaya, AH; Sincan, G; Turak, ET; Ilkkilic, K; Kuku, I; Aydogdu, I; Tekgunduz, E; Sencan, M; Albayrak, M; Berber, I; Karakus, V; Gemici, AI; Korkmaz, S; Keskin, A; Eser, B; Altuntas, F
  • No Thumbnail Available
    Item
    A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 Study
    Tekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Pamuk, GE; Altuntas, F; Sari, HI; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F
  • No Thumbnail Available
    Item
    A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study
    Tekgündüz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Altuntas, F; Sari, I; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F
    Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic plasma exchange (TPE) due to a presumptive diagnosis of TMA, who had serum ADAMTSI3 activity/antiADAMTS13 antibody analysis at the time of hospital admission. The median age of the study cohort was 36 (14-84). 67 (43.5%), 32 (20.8%), 27 (17.5%) and 28 (18.2%) patients were diagnosed as thrombotic thrombocytopenic purpura (TTP), infection/complement-associated hemolytic uremic syndrome (IA/CAHUS), secondary TMA and TMA-not otherwise specified (TMA-NOS), respectively. Patients received a median of 18 (1-75) plasma volume exchanges for 14 (153) days. 81 (52.6%) patients received concomitant steroid therapy with TPE. Treatment responses could be evaluated in 137 patients. 90 patients (65.7%) achieved clinical remission following TPE, while 47 (34.3%) patients had non-responsive disease. 25 (18.2%) non-responsive patients died during follow-up. Our study present real-life data on the distribution and follow-up of patients with TMAs who were referred to therapeutic apheresis centers for the application of TPE. (C) 2018 Elsevier Ltd. All rights reserved.